These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
401 related articles for article (PubMed ID: 21575627)
21. Brivaracetam does not modulate ionotropic channels activated by glutamate, γ-aminobutyric acid, and glycine in hippocampal neurons. Niespodziany I; Rigo JM; Moonen G; Matagne A; Klitgaard H; Wolff C Epilepsia; 2017 Nov; 58(11):e157-e161. PubMed ID: 28850675 [TBL] [Abstract][Full Text] [Related]
22. Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam. Kaminski RM; Gillard M; Leclercq K; Hanon E; Lorent G; Dassesse D; Matagne A; Klitgaard H Epilepsia; 2009 Jul; 50(7):1729-40. PubMed ID: 19486357 [TBL] [Abstract][Full Text] [Related]
23. Evaluating the In Vivo Specificity of [ Serrano ME; Becker G; Bahri MA; Seret A; Mestdagh N; Mercier J; Mievis F; Giacomelli F; Lemaire C; Salmon E; Luxen A; Plenevaux A Molecules; 2019 May; 24(9):. PubMed ID: 31052478 [TBL] [Abstract][Full Text] [Related]
24. Synthesis and Preclinical Evaluation of 11C-UCB-J as a PET Tracer for Imaging the Synaptic Vesicle Glycoprotein 2A in the Brain. Nabulsi NB; Mercier J; Holden D; Carré S; Najafzadeh S; Vandergeten MC; Lin SF; Deo A; Price N; Wood M; Lara-Jaime T; Montel F; Laruelle M; Carson RE; Hannestad J; Huang Y J Nucl Med; 2016 May; 57(5):777-84. PubMed ID: 26848175 [TBL] [Abstract][Full Text] [Related]
25. Preclinical In Vitro and In Vivo Characterization of Synaptic Vesicle 2A-Targeting Compounds Amenable to F-18 Labeling as Potential PET Radioligands for Imaging of Synapse Integrity. Patel S; Knight A; Krause S; Teceno T; Tresse C; Li S; Cai Z; Gouasmat A; Carroll VM; Barret O; Gottmukkala V; Zhang W; Xiang X; Morley T; Huang Y; Passchier J Mol Imaging Biol; 2020 Aug; 22(4):832-841. PubMed ID: 31728839 [TBL] [Abstract][Full Text] [Related]
26. Evaluation of 18F-UCB-H as a novel PET tracer for synaptic vesicle protein 2A in the brain. Warnock GI; Aerts J; Bahri MA; Bretin F; Lemaire C; Giacomelli F; Mievis F; Mestdagh N; Buchanan T; Valade A; Mercier J; Wood M; Gillard M; Seret A; Luxen A; Salmon E; Plenevaux A J Nucl Med; 2014 Aug; 55(8):1336-41. PubMed ID: 24935992 [TBL] [Abstract][Full Text] [Related]
27. Brivaracetam and Levetiracetam Suppress Astroglial L-Glutamate Release through Hemichannel via Inhibition of Synaptic Vesicle Protein. Fukuyama K; Okada M Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35562864 [TBL] [Abstract][Full Text] [Related]
28. A New SV2A Ligand for Epilepsy. Rogawski MA Cell; 2016 Oct; 167(3):587. PubMed ID: 27768878 [TBL] [Abstract][Full Text] [Related]
29. Brivaracetam: new compound approved for the treatment of epilepsy. Zaccara G Drugs Today (Barc); 2016 Apr; 52(4):219-27. PubMed ID: 27252986 [TBL] [Abstract][Full Text] [Related]
30. Solubilization and immunopurification of rat brain synaptic vesicle protein 2A with maintained binding properties. Lambeng N; Grossmann M; Chatelain P; Fuks B Neurosci Lett; 2006 May; 398(1-2):107-12. PubMed ID: 16434140 [TBL] [Abstract][Full Text] [Related]
31. Brivaracetam augments short-term depression and slows vesicle recycling. Yang X; Bognar J; He T; Mohammed M; Niespodziany I; Wolff C; Esguerra M; Rothman SM; Dubinsky JM Epilepsia; 2015 Dec; 56(12):1899-909. PubMed ID: 26515103 [TBL] [Abstract][Full Text] [Related]
32. Therapeutic Effects of Time-Limited Treatment with Brivaracetam on Posttraumatic Epilepsy after Fluid Percussion Injury in the Rat. Eastman CL; Fender JS; Klein P; D'Ambrosio R J Pharmacol Exp Ther; 2021 Dec; 379(3):310-323. PubMed ID: 34593559 [TBL] [Abstract][Full Text] [Related]
33. Characterization of [(3)H]ucb 30889 binding to synaptic vesicle protein 2A in the rat spinal cord. Lambeng N; Gillard M; Vertongen P; Fuks B; Chatelain P Eur J Pharmacol; 2005 Sep; 520(1-3):70-6. PubMed ID: 16125696 [TBL] [Abstract][Full Text] [Related]
34. Development of SV2A Ligands for Epilepsy Treatment: A Review of Levetiracetam, Brivaracetam, and Padsevonil. Wu PP; Cao BR; Tian FY; Gao ZB Neurosci Bull; 2024 May; 40(5):594-608. PubMed ID: 37897555 [TBL] [Abstract][Full Text] [Related]
35. Extrapolation of a Brivaracetam Exposure-Response Model from Adults to Children with Focal Seizures. Schoemaker R; Wade JR; Stockis A Clin Pharmacokinet; 2018 Jul; 57(7):843-854. PubMed ID: 28884437 [TBL] [Abstract][Full Text] [Related]
36. Brivaracetam (ucb 34714) inhibits Na(+) current in rat cortical neurons in culture. Zona C; Pieri M; Carunchio I; Curcio L; Klitgaard H; Margineanu DG Epilepsy Res; 2010 Jan; 88(1):46-54. PubMed ID: 19914041 [TBL] [Abstract][Full Text] [Related]
37. Brivaracetam (UCB 34714). von Rosenstiel P Neurotherapeutics; 2007 Jan; 4(1):84-7. PubMed ID: 17199019 [TBL] [Abstract][Full Text] [Related]
38. Combining modelling and mutagenesis studies of synaptic vesicle protein 2A to identify a series of residues involved in racetam binding. Shi J; Anderson D; Lynch BA; Castaigne JG; Foerch P; Lebon F Biochem Soc Trans; 2011 Oct; 39(5):1341-7. PubMed ID: 21936812 [TBL] [Abstract][Full Text] [Related]
39. Brivaracetam Population Pharmacokinetics and Exposure-Response Modeling in Adult Subjects With Partial-Onset Seizures. Schoemaker R; Wade JR; Stockis A J Clin Pharmacol; 2016 Dec; 56(12):1591-1602. PubMed ID: 27146213 [TBL] [Abstract][Full Text] [Related]
40. In vivo imaging of synaptic SV2A protein density in healthy and striatal-lesioned rats with [11C]UCB-J PET. Thomsen MB; Jacobsen J; Lillethorup TP; Schacht AC; Simonsen M; Romero-Ramos M; Brooks DJ; Landau AM J Cereb Blood Flow Metab; 2021 Apr; 41(4):819-830. PubMed ID: 32538280 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]